These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 12516047)
1. Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: human factor IX model. Krebsbach PH; Zhang K; Malik AK; Kurachi K J Gene Med; 2003 Jan; 5(1):11-7. PubMed ID: 12516047 [TBL] [Abstract][Full Text] [Related]
2. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion. Cherington V; Chiang GG; McGrath CA; Gaffney A; Galanopoulos T; Merrill W; Bizinkauskas CB; Hansen M; Sobolewski J; Levine PH; Greenberger JS; Hurwitz DR Hum Gene Ther; 1998 Jul; 9(10):1397-407. PubMed ID: 9681411 [TBL] [Abstract][Full Text] [Related]
3. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. Wen J; Vargas AG; Ofosu FA; Hortelano G J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997 [TBL] [Abstract][Full Text] [Related]
4. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. Wen J; Xu N; Li A; Bourgeois J; Ofosu FA; Hortelano G J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187 [TBL] [Abstract][Full Text] [Related]
5. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366 [TBL] [Abstract][Full Text] [Related]
6. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B]. Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526 [TBL] [Abstract][Full Text] [Related]
7. Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice. Daga A; Muraglia A; Quarto R; Cancedda R; Corte G Gene Ther; 2002 Jul; 9(14):915-21. PubMed ID: 12085239 [TBL] [Abstract][Full Text] [Related]
8. Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids. Sam MR; Azadbakhsh AS; Farokhi F; Rezazadeh K; Sam S; Zomorodipour A; Haddad-Mashadrizeh A; Delirezh N; Mokarizadeh A Biologicals; 2016 May; 44(3):170-7. PubMed ID: 26928674 [TBL] [Abstract][Full Text] [Related]
9. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle. Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894 [TBL] [Abstract][Full Text] [Related]
10. Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. Peng H; Chen ST; Wergedal JE; Polo JM; Yee JK; Lau KH; Baylink DJ Mol Ther; 2001 Aug; 4(2):95-104. PubMed ID: 11482980 [TBL] [Abstract][Full Text] [Related]
11. Local ex vivo gene therapy with bone marrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice. Zhang XS; Linkhart TA; Chen ST; Peng H; Wergedal JE; Guttierez GG; Sheng MH; Lau KH; Baylink DJ J Gene Med; 2004 Jan; 6(1):4-15. PubMed ID: 14716672 [TBL] [Abstract][Full Text] [Related]
12. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735 [TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hurwitz DR; Kirchgesser M; Merrill W; Galanopoulos T; McGrath CA; Emami S; Hansen M; Cherington V; Appel JM; Bizinkauskas CB; Brackmann HH; Levine PH; Greenberger JS Hum Gene Ther; 1997 Jan; 8(2):137-56. PubMed ID: 9017418 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice. Sclimenti CR; Neviaser AS; Baba EJ; Meuse L; Kay MA; Calos MP Biotechnol Prog; 2003; 19(1):144-51. PubMed ID: 12573017 [TBL] [Abstract][Full Text] [Related]
15. Expression of human factor IX cDNA in mice by implants of genetically modified skin fibroblasts from a hemophilia B patient. Zhou JM; Dai YF; Qiu XF; Hou GY; Akira Y; Xue JL Sci China B; 1993 Sep; 36(9):1082-92. PubMed ID: 8274202 [TBL] [Abstract][Full Text] [Related]
16. A study of the expression of functional human coagulation factor IX in keratinocytes using a nonviral vector regulated by K14 promoter. Hosseini SJ; Zomorodipour A; Jalal R; Sabouni F; Ataei F Appl Biochem Biotechnol; 2010 Nov; 162(6):1599-611. PubMed ID: 20397061 [TBL] [Abstract][Full Text] [Related]
17. A novel synthetic peptide vector system for optimal gene delivery to bone marrow stromal cells. Haitao P; Qixin Z; Xiaodong G J Pept Sci; 2007 Mar; 13(3):154-63. PubMed ID: 17154339 [TBL] [Abstract][Full Text] [Related]
18. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Ben-Shoshan J; Schwartz S; Luboshits G; Maysel-Auslender S; Barzelay A; Polak-Charcon S; Tzahor E; Barshack I; Barak A; Levkovitch-Verbin H; Keren G; George J Stem Cells; 2008 Oct; 26(10):2634-43. PubMed ID: 18687993 [TBL] [Abstract][Full Text] [Related]